Description:
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in
adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each
patient, using the patient's own circulating immune cells. First, Genocea confirms which
cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune
cells that recognize these cancer proteins are multiplied many times (a process called
PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in
one or more intravenous (IV) infusions.
Title
- Brief Title: TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
- Official Title: A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
GEN-011-101
- NCT ID:
NCT04596033
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Small-cell Lung Cancer
- Cutaneous Squamous Cell Carcinoma
- Anal Squamous Cell Carcinoma
Interventions
| Drug | Synonyms | Arms |
|---|
| GEN-011 | | Multiple Low Dose (MLD) |
| IL-2 | Interleukin-2 | Multiple Low Dose (MLD) |
| Fludarabine | | Single High Dose (SHD) |
| Cyclophosphamide | | Single High Dose (SHD) |
Purpose
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in
adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each
patient, using the patient's own circulating immune cells. First, Genocea confirms which
cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune
cells that recognize these cancer proteins are multiplied many times (a process called
PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in
one or more intravenous (IV) infusions.
Detailed Description
TiTAN-1 is an open-label, multicenter, first-in-human Phase 1 study of GEN-011 in patients
with melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and
neck (SCCHN), urothelial carcinoma (UC, bladder, ureter, urethra, or renal pelvis), renal
cell carcinoma (RCC), small cell lung cancer (SCLC), cutaneous squamous cell carcinoma
(CSCC), or anal squamous cell carcinoma (ASCC). Patients will be enrolled into one of 2
cohorts. One cohort will receive a multiple low dose (MLD) regimen of GEN-011 to be given
without lymphodepletion, and a second cohort will receive a single high dose (SHD) regimen of
GEN-011 after lymphodepletion. Regardless of cohort, each dose of GEN-011 will be followed by
a course of interleukin-2 (IL-2) as costimulatory therapy.
GEN-011 is an investigational, personalized neoantigen adoptive cell therapy (ACT) that is
being developed by Genocea for the treatment of adult patients with advanced solid tumors. A
proprietary tool developed by Genocea called ATLAS™ (Antigen Lead Acquisition System) will be
used to identify true immunogenic neoantigens from each patient's tumor that are recognized
by their own CD4 and/or CD8 T cells. ATLAS-identified neoantigens will be used to stimulate
and select autologous T cells collected by apheresis to generate an adoptive cell product ex
vivo.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Multiple Low Dose (MLD) | Experimental | GEN-011 is administered by IV infusion at 4-week intervals, up to 5 doses maximum. Each dose is followed by IL-2 administration. MLD patients will not undergo lymphodepletion. | |
| Single High Dose (SHD) | Experimental | GEN-011 is administered as a single IV infusion at the maximum available cell yield, after the patient completes a fludarabine/cyclophosphamide lymphodepletion regimen. The single GEN-011 dose is followed by IL-2 administration. | - GEN-011
- IL-2
- Fludarabine
- Cyclophosphamide
|
Eligibility Criteria
Inclusion Criteria:
- Consents to study procedures
- Diagnosis of one of the following solid tumors: cutaneous melanoma, non-small cell
lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial
carcinoma (UC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), cutaneous
squamous cell carcinoma (CSCC), anal squamous cell carcinoma (ASCC)
- Received, been intolerant of, or been ineligible to receive standard of care treatment
regimen.
- Measurable disease per RECIST criteria
- Life expectancy > 6 months and ECOG status 0 or 1
- Capacity to tolerate lymphodepletion (SHD group only) and IL-2 therapy
- Tumor tissue available
- Willing to use contraceptives for 90 days after receiving GEN-011, and not currently
pregnant.
- Adequate blood, liver, kidney, and lung function
- Sufficient stimulatory neoantigens identified in ATLAS
Exclusion Criteria:
- Receiving immunosuppressive medications
- Serious ongoing viral, bacterial, or fungal infection
- History of cardiac arrythmias or significant heart block
- History of leptomeningeal carcinomatosis
- Active autoimmune disease
- Portal vein thrombosis
- Malignant disease other than those treated in this study
- Receiving other investigational anti-cancer therapy
- Prior stem cell or solid organ transplant
- Primary immune deficiency disease
- Significant ongoing toxicities from prior therapies
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Incidence of Treatment-Emergent Adverse Events |
| Time Frame: | 2 years after first GEN-011 infusion |
| Safety Issue: | |
| Description: | Adverse events will be graded according to the NC Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 |
Secondary Outcome Measures
| Measure: | T cell responses to GEN-011 |
| Time Frame: | 2 years after first GEN-011 infusion |
| Safety Issue: | |
| Description: | Antigen-specific immunogenicity assays |
| Measure: | Duration of response |
| Time Frame: | 2 years after first GEN-011 infusion |
| Safety Issue: | |
| Description: | Measured by RECIST |
| Measure: | Progression-free survival |
| Time Frame: | 2 years after first GEN-011 infusion |
| Safety Issue: | |
| Description: | Length of time without disease progression |
| Measure: | Overall survival |
| Time Frame: | From first GEN-011 infusion through study completion, at least 2 years |
| Safety Issue: | |
| Description: | Length of time patient remains alive |
Details
| Phase: | Phase 1 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | Genocea Biosciences, Inc. |
Trial Keywords
- Personalized
- Immunotherapy
- Solid Tumor
- Personal
- Cell Therapy
- Carcinoma
- Melanoma
- Lung
- Bladder
- Cancer
- Kidney
- Anal
- Squamous
- TiTAN
- ATLAS
- PLANET
- TiTAN-1
- Autologous
- Neoantigen
Last Updated
July 15, 2021
